Matrixx, Zila settlement
This article was originally published in The Tan Sheet
Executive Summary
Zila's existing swab supply agreement with Matrixx extended 90 days to March 31, 2004 under a litigation settlement announced Aug. 14. However, "it is unlikely that the contract will be renewed at that time," Zila says. Under the pact, Matrixx accepted Zila's current production level and swab price increases, Zila says. Matrixx, which markets Zicam Cold Remedy Swabs, filed suit in Arizona state court in April, alleging that Zila breached its supply contract by not producing agreed-upon levels of swabs and raising prices (1"The Tan Sheet" April 28, 2003, In Brief)...
You may also be interested in...
Matrixx v. Zila
Matrixx Initiatives' request for temporary restraining order against Zila Pharmaceuticals Swab Technologies has been denied, Zila announces April 23. Phoenix, Ariz.-based firm says Matrixx' claims Zila breached a swab-manufacturing contract by failing to produce requested levels of swabs and raising swab prices "are wholly without merit." Zila intends "to vigorously defend these actions," has filed motion to dismiss remainder of case. Matrixx filed claim April 4 in Arizona state court, seeking temporary restraining order and monetary damages...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.